A detailed history of Handelsbanken Fonder Ab transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 29,100 shares of CRSP stock, worth $1.18 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
29,100
Previous 100,300 70.99%
Holding current value
$1.18 Million
Previous $5.42 Million 74.76%
% of portfolio
0.01%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 04, 2024

SELL
$44.62 - $62.75 $3.18 Million - $4.47 Million
-71,200 Reduced 70.99%
29,100 $1.37 Million
Q2 2024

Aug 05, 2024

BUY
$51.17 - $68.18 $4.28 Million - $5.7 Million
83,600 Added 500.6%
100,300 $5.42 Million
Q1 2024

May 13, 2024

BUY
$60.67 - $89.12 $60,670 - $89,120
1,000 Added 6.37%
16,700 $1.14 Million
Q4 2023

Feb 01, 2024

BUY
$38.62 - $72.18 $65,654 - $122,706
1,700 Added 12.14%
15,700 $983,000
Q2 2023

Aug 02, 2023

BUY
$43.47 - $67.77 $65,205 - $101,655
1,500 Added 12.0%
14,000 $786,000
Q4 2022

Feb 07, 2023

BUY
$39.19 - $65.67 $105,813 - $177,309
2,700 Added 27.55%
12,500 $508,000
Q2 2022

Aug 03, 2022

SELL
$43.23 - $73.83 $12,968 - $22,149
-300 Reduced 2.97%
9,800 $596,000
Q3 2021

Nov 10, 2021

SELL
$110.2 - $156.64 $11,020 - $15,663
-100 Reduced 0.98%
10,100 $1.13 Million
Q2 2021

Aug 03, 2021

BUY
$100.84 - $161.89 $131,092 - $210,456
1,300 Added 14.61%
10,200 $1.65 Million
Q4 2020

Feb 11, 2021

SELL
$79.67 - $173.23 $191,208 - $415,752
-2,400 Reduced 21.24%
8,900 $1.36 Million
Q3 2020

Nov 13, 2020

BUY
$78.5 - $100.64 $416,050 - $533,392
5,300 Added 88.33%
11,300 $945,000
Q2 2020

Aug 26, 2020

BUY
$38.5 - $76.05 $231,000 - $456,300
6,000 New
6,000 $441,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.18B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Handelsbanken Fonder Ab Portfolio

Follow Handelsbanken Fonder Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Handelsbanken Fonder Ab with notifications on news.